Tradestie Institutional Equity Comparison Engine

CASI vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CASI trades at N/M Forward P/E with -333.1% operating margin (-60.5% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, CASI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CASI N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -333.1% vs -485.4% ยท YoY -60.5% vs +408.6%
Momentum & Technical Winner SRZN
1Y -91.4% vs +110.8% ยท 52W Pos 0% vs 63%
Options & Structure Winner SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (13th %ile IV)
CASI NASDAQ
CASI Pharmaceuticals, Inc. Ordinary Shares
Pharmaceutical Preparations
$0.21
-74.06% 1D
Market Cap $12.4M
1M Return -78.83%
1Y Return -91.43%
Forward P/E N/M
Unified AI Score
44.7 / 100 HOLD
Tech 40.0 Fund 44.0 Flow 50.0 Mom 44.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
1M Return +10.52%
1Y Return +110.81%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CASI -91.43% SRZN +110.81% Spread: +182.93 pp (SRZN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CASI TTM Op. Margin: -333.1% SRZN TTM Op. Margin: -485.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CASI vs SRZN. Trailing 12-month operating profitability (CASI -333.1% vs SRZN -485.4%) and valuation multiples (CASI N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CASI (2) vs SRZN (6)
Institutional Metric CASI SRZN Criterion Row Winner
Market Capitalization Scale $12.4M $642.7M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -60.5% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability -333.1% -485.4% Higher Margin CASI
Net Profit Margin Profitability -184.0% 0.0% Higher Margin SRZN
Return on Equity (ROE) Capital Efficiency -1094.5% -62.8% Higher ROE SRZN
52-Week Range Position Momentum 0% ($0โ€“$3) 63% ($13โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 0.95ฮฒ ยท 240% Vol 1.29ฮฒ ยท 73% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 44.7 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite CASI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CASI vs SRZN Buy Guide
CASI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CASI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CASI nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.